pnt2258
Nucleic acidexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2010 (NCT01191775)
Timeline
Indications
Mechanism of action
- Apoptosis regulator Bcl-2INHIBITOR
BCL2 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- pnt100
- pnt2258
- pnt2258
- pnt2258
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02378038 | Phase 2 | Aug 1, 2015 | Sierra Oncology, Inc. |
| NCT02226965 | Phase 2 | Dec 1, 2014 | Sierra Oncology, Inc. |
| NCT01733238 | Phase 2 | Nov 1, 2012 | Sierra Oncology, Inc., St. John Hospital and Medical Center, Van Elslander Cancer Center |
| NCT01191775 | Phase 1 | Aug 1, 2010 | Sierra Oncology, Inc., South Texas Accelerated Research Therapeutics |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sierra Oncology, Inc. | For profit | 4 | 4 | 2 | 2010 |
| South Texas Accelerated Research Therapeutics | For profit | 1 | 0 | 1 | 2010 |
| St. John Hospital and Medical Center, Van Elslander Cancer Center | Academic/Hospital | 1 | 0 | 1 | 2012 |
3 organizations
Page 1 / 1